JP2014503480A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503480A5
JP2014503480A5 JP2013536727A JP2013536727A JP2014503480A5 JP 2014503480 A5 JP2014503480 A5 JP 2014503480A5 JP 2013536727 A JP2013536727 A JP 2013536727A JP 2013536727 A JP2013536727 A JP 2013536727A JP 2014503480 A5 JP2014503480 A5 JP 2014503480A5
Authority
JP
Japan
Prior art keywords
deuterium
rich
pharmaceutical composition
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013536727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503480A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/057698 external-priority patent/WO2012058219A2/en
Publication of JP2014503480A publication Critical patent/JP2014503480A/ja
Publication of JP2014503480A5 publication Critical patent/JP2014503480A5/ja
Pending legal-status Critical Current

Links

JP2013536727A 2010-10-26 2011-10-25 ジュウテリウムリッチなラサギリン Pending JP2014503480A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40674010P 2010-10-26 2010-10-26
US61/406,740 2010-10-26
PCT/US2011/057698 WO2012058219A2 (en) 2010-10-26 2011-10-25 Deuterium enriched rasagiline

Publications (2)

Publication Number Publication Date
JP2014503480A JP2014503480A (ja) 2014-02-13
JP2014503480A5 true JP2014503480A5 (https=) 2014-12-11

Family

ID=45973513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013536727A Pending JP2014503480A (ja) 2010-10-26 2011-10-25 ジュウテリウムリッチなラサギリン

Country Status (17)

Country Link
US (2) US20120101168A1 (https=)
EP (1) EP2632254A4 (https=)
JP (1) JP2014503480A (https=)
KR (1) KR20140023872A (https=)
CN (1) CN103188933A (https=)
AU (1) AU2011320611A1 (https=)
BR (1) BR112013010308A2 (https=)
CA (1) CA2816104A1 (https=)
CL (1) CL2013001101A1 (https=)
EA (1) EA201390613A1 (https=)
IL (1) IL225852A0 (https=)
MX (1) MX2013004598A (https=)
NZ (1) NZ610526A (https=)
PH (1) PH12013500821A1 (https=)
SG (2) SG189454A1 (https=)
WO (1) WO2012058219A2 (https=)
ZA (1) ZA201303505B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド R(+)−n−メチル−プロパルギルアミノインダン
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体
CN111323524B (zh) * 2020-04-08 2022-04-15 重庆华森制药股份有限公司 一种炔丙胺及其杂质的检测方法
CN115947675B (zh) * 2022-12-21 2024-05-31 博济医药科技股份有限公司 一种雷沙吉兰中间体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
AU2006245349A1 (en) * 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
EP1948248A2 (en) * 2005-11-06 2008-07-30 Katz-Brull, Rachel Magnetic resonance imaging and spectroscopy means and methods thereof
AU2009254929B2 (en) * 2008-06-02 2014-03-13 Generics [Uk] Limited An improved process for the preparation of amines
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
US20100172916A1 (en) * 2008-11-10 2010-07-08 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
US20120156139A1 (en) * 2009-08-31 2012-06-21 Rachel Katz-Brull Isotopically labeled neurochemical agents and uses therof for diagnosing conditions and disorders

Similar Documents

Publication Publication Date Title
JP2014503480A5 (https=)
JP5373405B2 (ja) 選択的アンドロゲン受容体モジュレーター
EP2912047B1 (en) Antiviral phosphonate analogues and process for preparation thereof
CN105873589B (zh) 制造苯并喹啉化合物的方法
IL255433B2 (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP2020520946A5 (https=)
EP4293009A2 (en) Fenfluramine compositions and methods of preparing the same
WO2019177975A1 (en) Antibiotics effective for gram-negative pathogens
CN103188933A (zh) 富集氘的雷沙吉兰
JP2007522162A5 (https=)
EP2315748A1 (en) Processes for the preparation of 4-oxo-octahydro-indole-1-carbocylic acid methyl ester and derivatives thereof
JP5955364B2 (ja) 中間体として有用な新規化合物
CN108484550A (zh) 一种含笑内酯衍生物及其制备方法和用途
JP2018510189A5 (https=)
KR20170002433A (ko) 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
JP6908657B2 (ja) 4−[2−ジメチルアミノ−1−(1−ヒドロキシシクロヘキシル)エチル]フェニル4−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
CN108210933B (zh) 一种地佐辛与聚乙二醇的结合物
CN103764608B (zh) 用于治疗炎性肠病的茚衍生物
CN111909174A (zh) 吡啶酮衍生物的晶型及制备方法和应用
CN114286811B (zh) 富马酸单甲酯的前药
WO2018053587A1 (en) Compositions for the treatment of hypertension and/or fibrosis
TW200823172A (en) GABA analogs, compositions and method for manufacturing thereof
WO2024213129A1 (zh) 一种酰乙酯多环化合物及其药物组合物和用途
CN102633852A (zh) 亚胺类豆甾醇衍生物及其在抗癌药物中的应用
US20030096004A1 (en) (S,S'),(S,R')-amphetaminil, compositions and uses thereof